Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) morphologic, qualitative, semiquantitative, and radiomics features predicting undifferentiated pleomorphic sarcoma (UPS) treatment response
Undifferentiated pleomorphic sarcoma (UPS) is the largest subgroup of soft tissue sarcomas. This study determined the value of perfusion-weighted imaging with dynamic-contrast-enhancement (PWI/DCE) morphologic, qualitative, and semiquantitative features for predicting UPS pathology-assessed treatment effect (PATE). This retrospective study included 33 surgically excised extremity UPS patients with pre-surgical MRI. Volumetric tumor segmentation from PWI/DCE was obtained at Baseline (BL), Post-Chemotherapy (PC), and Post-Radiation Therapy (PRT). The surgical specimens' PATE separated cases into Responders (R) (≥ 90%, 16 patients), Partial-Responders (PR) (89 - 31%, 10 patients), and Non-Responders (NR) (≤ 30%, seven patients). Seven semiquantitative kinetic parameters and maps were extracted from time-intensity curves (TICs), and 107 radiomic features were derived. Statistical analyses compared R vs. PR/NR. At PRT, 79% of R displayed a "Capsular" morphology (P = 1.49 × 10<sup>-7</sup>), and 100% demonstrated a TIC-type II (P = 8.32 × 10<sup>-7</sup>). 80% of PR showed "Unipolar" morphology (P = 1.03 × 10<sup>-5</sup>), and 60% expressed a TIC-type V (P = 0.06). Semiquantitative wash-in rate (WiR) was able to separate R vs. PR/NR (P = 0.0078). The WiR radiomics displayed significant differences in the first_order_10 percentile (P = 0.0178) comparing R vs. PR/NR at PRT. The PWI/DCE TIC-type II curve, low WiR, and "Capsular" enhancement represent PRT patterns typically observed in successfully treated UPS and demonstrate potential for UPS treatment response assessment.
Authors
- Andrew Justin Bishop (ORCID: https://orcid.org/0000-0002-7737-8023)
- Ken‐Pin Hwang (ORCID: https://orcid.org/0000-0002-8196-3794)
- Chia-Chin Wu (ORCID: https://orcid.org/0000-0002-5208-6016)
- R. Jason Stafford (ORCID: https://orcid.org/0000-0003-4091-8417)
- John E. Madewell (ORCID: https://orcid.org/0000-0001-8543-7188)
- Jinli Ma
- Elvis Duran-Sierra (ORCID: https://orcid.org/0000-0003-0077-8499)
- Raúl Valenzuela (ORCID: https://orcid.org/0000-0002-1682-5889)
- Robert S. Benjamin (ORCID: https://orcid.org/0000-0002-2589-5870)
- Simon S. Lo (ORCID: https://orcid.org/0000-0002-3744-4065)
- Keila E. Torres (ORCID: https://orcid.org/0000-0002-1855-0989)
- Rajendra Kumar (ORCID: https://orcid.org/0000-0002-5075-1473)
- Behrang Amini (ORCID: https://orcid.org/0000-0002-4962-3466)
- Alexandra M. Zarzour
- William A. Murphy (ORCID: https://orcid.org/0000-0002-7333-2642)
- Mathew A. Canjirathinkal
- Wang Wl
- Colleen M. Costelloe
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1038/s41598-024-72780-7
- Citations
- 7
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.93